Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Treatment for Colorectal Liver Metastases Using Heparin, Dexamethasone, and Floxuridine for Patients with Heavy Tumor Burden

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for Colorectal Liver Metastases, which are cancerous growths that have spread to the liver from the colon or rectum. The study will use several medications, including Heparin, a blood thinner, Dexamethasone Acetate, a type of steroid, Dexamethasone Sodium Phosphate, another form of steroid, and Floxuridine, a chemotherapy drug. The purpose of the study is to evaluate the effectiveness of these treatments in improving overall survival over a period of two years.

Participants in the study will receive one or more of these medications through an intravenous infusion, which means the medicine is delivered directly into the bloodstream. The study will compare the effects of these medications on the participants' health, including their ability to control the cancer and improve quality of life. Some participants may receive a placebo, which is a substance with no active medication, to help researchers understand the true effects of the treatments being tested.

The study will last for several years, with regular check-ups and assessments to monitor the participants' health and response to the treatment. The goal is to determine if these medications can help patients live longer and manage their cancer more effectively. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient must have a confirmed diagnosis of colorectal liver metastases. The patient should have previously received at least one line of systemic chemotherapy.

    The patient must meet specific health criteria, including satisfactory blood tests and a good performance status. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception.

  2. Step 2

    Treatment initiation

    The treatment involves the administration of medications in the form of a concentrate for solution for infusion. The medications include heparin, dexamethasone acetate, dexamethasone sodium phosphate, and floxuridine.

    The specific dosage, frequency, and duration of administration will be determined by the healthcare provider based on the patient's condition and response to treatment.

  3. Step 3

    Monitoring and evaluation

    Throughout the trial, the patient's health and response to treatment will be closely monitored. This includes regular blood tests and imaging studies to assess the status of liver metastases.

    The primary goal is to evaluate overall survival at two years, with secondary goals including progression-free survival, overall survival at five years, resection or transplantation rate, and quality of life.

  4. Step 4

    Completion of the trial

    The trial is expected to continue until October 31, 2033. The patient's participation will be concluded based on the trial's timeline or if specific health criteria are met.

    Upon completion, the patient's overall health and treatment outcomes will be assessed to determine the effectiveness of the treatment regimen.

Who can join the trial?

18 criteria

  • The patient must have a type of cancer called adenocarcinoma in the colon or rectum, which has been confirmed by a test called histology.
  • The patient must have cancer that has spread to the liver, known as liver metastases, and meet one of the following conditions:
    • The liver tumors cannot be removed by surgery at the time of joining the study.
    • Surgery would require the tumors to shrink by 10% or more.
    • The patient needs a new type of chemotherapy because the current one is not working well, or it was stopped due to side effects.
    • The patient has a stable or partially reduced tumor size after the first round of chemotherapy but is unlikely to have surgery due to having many tumors in both sides of the liver or very large tumors.
    • The patient must have received at least one type of chemotherapy before joining the study and be planned for another type of chemotherapy.
    • If the patient has started a new chemotherapy, they must join the study before the first evaluation of this new treatment.
    • The patient must be in good health overall, with a performance status of 0 or 1, which means they are fully active or have some symptoms but can still do light work.
    • The patient must have satisfactory blood test results, including:
      • Hemoglobin (Hb) level above 9 g/dl.
      • Neutrophils (a type of white blood cell) above 1.0 after any treatment to boost them.
      • Platelets (TRC) above 75.
      • Bilirubin (a liver function test) less than 1.5 times the normal level.
      • Liver enzymes (ASAT, ALAT) less than 5 times the normal level.
      • Creatinine (a kidney function test) less than 1.25 times the normal level.
      • Albumin (a protein in the blood) above the lower normal level.
      • Women who can have children must have a confirmed menstrual cycle and a negative pregnancy test before joining the study, and agree to use a highly effective birth control method during the study and for 30 days after.
      • Men who may have sexual relations with women who can have children must agree to use a condom during the study and for 90 days after.
      • The patient must sign a document called informed consent, agreeing to participate in the study and follow the treatment and check-up schedule.

Who cannot join the trial?

3 criteria

  • Patients with medical conditions other than **Colorectal Liver Metastases** cannot participate.
  • Individuals who are not within the specified age range cannot participate. The age range is not specified here, but it is important for eligibility.
  • Participants must not belong to a vulnerable population. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Extended Criteria Treatment is a therapy being studied for its effectiveness in treating liver metastases with a heavy tumor burden. This treatment aims to improve the overall survival of patients over a period of two years. The specific details of the treatment are not provided, but it is part of a clinical trial focused on patients with significant liver metastases.

What is already known about the treatment

Bevacizumab – Bevacizumab is administered through an intravenous infusion, meaning it is given directly into a vein. It is currently well-established in medical literature and is used in the treatment of various cancers, including colorectal liver metastases. The main therapeutic indication for Bevacizumab is to inhibit the growth of blood vessels that supply tumors, thereby slowing or stopping tumor growth. At the molecular level, it works by blocking a protein called vascular endothelial growth factor (VEGF), which is responsible for the formation of new blood vessels. Bevacizumab is classified as a monoclonal antibody in pharmacology.

Investigated diseases

Colorectal Liver Metastases – This condition occurs when cancer cells from the colon or rectum spread to the liver. It is a common progression for colorectal cancer, as the liver is a frequent site for metastasis due to its blood supply. The disease often develops without symptoms initially, but as it progresses, it may cause abdominal pain, weight loss, and jaundice. The growth of metastatic tumors in the liver can affect liver function and overall health. Over time, the liver's ability to process nutrients and filter toxins may be compromised. The progression of the disease can vary, with some cases remaining stable for a period while others may advance more rapidly.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512397-95-00Estimated enrolment97 patientsSponsorOslo University Hospital HF

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).